Cancer immunotherapies targeting the PD-1 signaling pathway

Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwai, Yoshiko, Hamanishi, Junzo, Chamoto, Kenji, Honjo, Tasuku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381059/
https://www.ncbi.nlm.nih.gov/pubmed/28376884
http://dx.doi.org/10.1186/s12929-017-0329-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381059/
https://www.ncbi.nlm.nih.gov/pubmed/28376884
http://dx.doi.org/10.1186/s12929-017-0329-9

Ejemplares similares